News Allergan ‘not looking for big deals’ as growth slows Company will put its $27 billion to use, however
News Merck, Allergan named as potential bidders for Biogen Biogen vulnerable to takeover as chief executive steps down
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.